Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the phase III SQUIRE trial in patients with non-small cell lung cancer (NSCLC) treated with necitumumab.
Reck says the rash was the only major adverse event observed, but it is easily manageable. Doses can be modified and topical treatments can be used.
Reck and his team are pleased with the results and improvements of the trial, and they believe it has presented a crucial new option for the treatment paradigm.
Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the phase III SQUIRE trial, which investigated patients with non-small cell lung cancer (NSCLC) treated with necitumumab.
In Second-Line, Atezolizumab/Cabozantinib Shows No Benefit Over SOC in NSCLC
March 31st 2023At the 2023 European Lung Cancer Congress, results from the recent findings of the CONTACT-01 trial showed no benefit for patients with metastatic non–small cell lung cancer on the combination of atezolizumab and cabozantinib compared with the standard of care.
Read More
Expert Stresses Importance of Transportation Security to Improve Cancer Care
March 29th 2023In an interview, Krisda Chaiyachati, MD, MPH, discussed some of the social determinants of health for patients with cancer and some of the challenges patients undergoing treatment face, including transportation insecurity.
Read More
Considering Targeted Therapies When Managing Young Patients With mCRC
March 27th 2023In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.
Read More
2 Clarke Drive
Cranbury, NJ 08512